PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications

The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to treat. Among these, there are the poorly differentiated and anaplastic thyroid cancers, unresponsive to all the therapies curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulisse, Salvatore, Tuccilli, Chiara, Sorrenti, Salvatore, Antonelli, Alessandro, Fallahi, Poupak, D’Armiento, Eleonora, Catania, Antonio, Tartaglia, Francesco, Amabile, Maria Ida, Giacomelli, Laura, Metere, Alessio, Cornacchini, Nicola, Pironi, Daniele, Carbotta, Giovanni, Vergine, Massimo, Monti, Massimo, Baldini, Enke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471477/
https://www.ncbi.nlm.nih.gov/pubmed/30897754
http://dx.doi.org/10.3390/ijms20061405
Descripción
Sumario:The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to treat. Among these, there are the poorly differentiated and anaplastic thyroid cancers, unresponsive to all the therapies currently in use. In the present review we will summarize information regarding the expression of PD-L1 in the different thyroid cancer histotypes, its correlation with clinicopathological features, and its potential prognostic value. Then, we will evaluate the available data indicating the PD-1/PD-L1 axis as a promising target for thyroid cancer therapy.

Ejemplares similares